The leucine aminopeptidase of Staphylococcus aureus is secreted and contributes to biofilm formation

Arun Kumar Singh, Rochika Singh, Dhanendra Tomar, Chirayu D. Pandya, Rajesh Singh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Staphylococcus aureus has emerged as a major drug-resistant pathogen in hospital- and community-acquired infections. Leucine aminopeptidase (LAP) is known to be essential for survival of the bacteria; however the LAP of S. aureus has not been extensively characterized. In this study, we report a detailed characterization of the S. aureus LAP. Methods: LAP from S. aureus was cloned, purified, and further biochemically characterized. The expression of LAP was analyzed by Western blotting. Growth and biofilm formation were analyzed spectrophotometrically. Results: LAP was cloned from S. aureus and expressed as a 55 kDa protein, whereas the molecular weight of the native protein is approximately 600 kDa. LAP showed amidolytic activity against l-leucine p-nitroanilide. Optimal activity was observed at pH 8.5 and 37°C with a Vmax of 2500μmol/min/mg protein. LAP enzymatic activity was inhibited by ion chelators and enhanced by divalent metal ions, specifically Ni. LAP is secreted by laboratory as well as clinical strains. Bestatin, an inhibitor of LAP, inhibits S. aureus growth and biofilm formation. Conclusions: To our knowledge, this is the first detailed characterization of LAP from S. aureus and suggests its importance in survival and pathogenesis.

Original languageEnglish (US)
Pages (from-to)e375-e381
JournalInternational Journal of Infectious Diseases
Volume16
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Leucyl Aminopeptidase
Biofilms
Staphylococcus aureus
Ions
Community-Acquired Infections
Proteins
Chelating Agents
Growth
Leucine
Molecular Weight
Western Blotting
Metals

Keywords

  • Bestatin
  • Biofilm
  • Leucine aminopeptidase
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

The leucine aminopeptidase of Staphylococcus aureus is secreted and contributes to biofilm formation. / Singh, Arun Kumar; Singh, Rochika; Tomar, Dhanendra; Pandya, Chirayu D.; Singh, Rajesh.

In: International Journal of Infectious Diseases, Vol. 16, No. 5, 01.05.2012, p. e375-e381.

Research output: Contribution to journalArticle

Singh, Arun Kumar ; Singh, Rochika ; Tomar, Dhanendra ; Pandya, Chirayu D. ; Singh, Rajesh. / The leucine aminopeptidase of Staphylococcus aureus is secreted and contributes to biofilm formation. In: International Journal of Infectious Diseases. 2012 ; Vol. 16, No. 5. pp. e375-e381.
@article{b85d94ab3e6a414dbdb1f2c0a540e9cf,
title = "The leucine aminopeptidase of Staphylococcus aureus is secreted and contributes to biofilm formation",
abstract = "Background: Staphylococcus aureus has emerged as a major drug-resistant pathogen in hospital- and community-acquired infections. Leucine aminopeptidase (LAP) is known to be essential for survival of the bacteria; however the LAP of S. aureus has not been extensively characterized. In this study, we report a detailed characterization of the S. aureus LAP. Methods: LAP from S. aureus was cloned, purified, and further biochemically characterized. The expression of LAP was analyzed by Western blotting. Growth and biofilm formation were analyzed spectrophotometrically. Results: LAP was cloned from S. aureus and expressed as a 55 kDa protein, whereas the molecular weight of the native protein is approximately 600 kDa. LAP showed amidolytic activity against l-leucine p-nitroanilide. Optimal activity was observed at pH 8.5 and 37°C with a Vmax of 2500μmol/min/mg protein. LAP enzymatic activity was inhibited by ion chelators and enhanced by divalent metal ions, specifically Ni. LAP is secreted by laboratory as well as clinical strains. Bestatin, an inhibitor of LAP, inhibits S. aureus growth and biofilm formation. Conclusions: To our knowledge, this is the first detailed characterization of LAP from S. aureus and suggests its importance in survival and pathogenesis.",
keywords = "Bestatin, Biofilm, Leucine aminopeptidase, Staphylococcus aureus",
author = "Singh, {Arun Kumar} and Rochika Singh and Dhanendra Tomar and Pandya, {Chirayu D.} and Rajesh Singh",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.ijid.2012.01.009",
language = "English (US)",
volume = "16",
pages = "e375--e381",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The leucine aminopeptidase of Staphylococcus aureus is secreted and contributes to biofilm formation

AU - Singh, Arun Kumar

AU - Singh, Rochika

AU - Tomar, Dhanendra

AU - Pandya, Chirayu D.

AU - Singh, Rajesh

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Background: Staphylococcus aureus has emerged as a major drug-resistant pathogen in hospital- and community-acquired infections. Leucine aminopeptidase (LAP) is known to be essential for survival of the bacteria; however the LAP of S. aureus has not been extensively characterized. In this study, we report a detailed characterization of the S. aureus LAP. Methods: LAP from S. aureus was cloned, purified, and further biochemically characterized. The expression of LAP was analyzed by Western blotting. Growth and biofilm formation were analyzed spectrophotometrically. Results: LAP was cloned from S. aureus and expressed as a 55 kDa protein, whereas the molecular weight of the native protein is approximately 600 kDa. LAP showed amidolytic activity against l-leucine p-nitroanilide. Optimal activity was observed at pH 8.5 and 37°C with a Vmax of 2500μmol/min/mg protein. LAP enzymatic activity was inhibited by ion chelators and enhanced by divalent metal ions, specifically Ni. LAP is secreted by laboratory as well as clinical strains. Bestatin, an inhibitor of LAP, inhibits S. aureus growth and biofilm formation. Conclusions: To our knowledge, this is the first detailed characterization of LAP from S. aureus and suggests its importance in survival and pathogenesis.

AB - Background: Staphylococcus aureus has emerged as a major drug-resistant pathogen in hospital- and community-acquired infections. Leucine aminopeptidase (LAP) is known to be essential for survival of the bacteria; however the LAP of S. aureus has not been extensively characterized. In this study, we report a detailed characterization of the S. aureus LAP. Methods: LAP from S. aureus was cloned, purified, and further biochemically characterized. The expression of LAP was analyzed by Western blotting. Growth and biofilm formation were analyzed spectrophotometrically. Results: LAP was cloned from S. aureus and expressed as a 55 kDa protein, whereas the molecular weight of the native protein is approximately 600 kDa. LAP showed amidolytic activity against l-leucine p-nitroanilide. Optimal activity was observed at pH 8.5 and 37°C with a Vmax of 2500μmol/min/mg protein. LAP enzymatic activity was inhibited by ion chelators and enhanced by divalent metal ions, specifically Ni. LAP is secreted by laboratory as well as clinical strains. Bestatin, an inhibitor of LAP, inhibits S. aureus growth and biofilm formation. Conclusions: To our knowledge, this is the first detailed characterization of LAP from S. aureus and suggests its importance in survival and pathogenesis.

KW - Bestatin

KW - Biofilm

KW - Leucine aminopeptidase

KW - Staphylococcus aureus

UR - http://www.scopus.com/inward/record.url?scp=84862819734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862819734&partnerID=8YFLogxK

U2 - 10.1016/j.ijid.2012.01.009

DO - 10.1016/j.ijid.2012.01.009

M3 - Article

C2 - 22410279

AN - SCOPUS:84862819734

VL - 16

SP - e375-e381

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

SN - 1201-9712

IS - 5

ER -